BioXcel Therapeutics, Inc.

NasdaqCM:BTAI Voorraadrapport

Marktkapitalisatie: US$26.2m

BioXcel Therapeutics Toekomstige groei

Future criteriumcontroles 2/6

BioXcel Therapeutics is forecast to grow earnings and revenue by 17.2% and 57.7% per annum respectively while EPS is expected to grow by 43.8% per annum.

Belangrijke informatie

17.2%

Groei van de winst

43.8%

Groei van de winst per aandeel

Biotechs winstgroei27.1%
Inkomstengroei57.7%
Toekomstig rendement op eigen vermogenn/a
Dekking van analisten

Low

Laatst bijgewerkt21 Oct 2024

Recente toekomstige groei-updates

Recent updates

Shareholders May Be More Conservative With BioXcel Therapeutics, Inc.'s (NASDAQ:BTAI) CEO Compensation For Now

Jun 04
Shareholders May Be More Conservative With BioXcel Therapeutics, Inc.'s (NASDAQ:BTAI) CEO Compensation For Now

BioXcel Therapeutics: Igalmi's Commercial Uncertainty Remains, Downgrading To A Hold

Aug 28

Winst- en omzetgroeiprognoses

NasdaqCM:BTAI - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
12/31/202620-71-66-703
12/31/202510-83-77-985
12/31/20245-78-85-925
6/30/20242-108-105-105N/A
3/31/20242-153-120-120N/A
12/31/20231-179-155-155N/A
9/30/20231-212-167-167N/A
6/30/20231-203-160-160N/A
3/31/20231-187-155-155N/A
12/31/20220-166-135-135N/A
9/30/20220-137-117-117N/A
6/30/2022N/A-122-106-106N/A
3/31/2022N/A-112-95-95N/A
12/31/2021N/A-107-83-82N/A
9/30/2021N/A-102-83-82N/A
6/30/2021N/A-100-82-81N/A
3/31/2021N/A-94-74-74N/A
12/31/2020N/A-82-67-66N/A
9/30/2020N/A-69-54-54N/A
6/30/2020N/A-54-42-42N/A
3/31/2020N/A-41-34-34N/A
12/31/2019N/A-33-28-27N/A
9/30/2019N/A-32-25-24N/A
6/30/2019N/A-28-20-19N/A
3/31/2019N/A-22-19-18N/A
12/31/2018N/A-19-14-14N/A
9/30/2018N/A-15-10-10N/A
6/30/2018N/A-11-8-7N/A
3/31/2018N/A-8N/A-3N/A
12/31/2017N/A-5N/A-2N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: BTAI is forecast to remain unprofitable over the next 3 years.

Winst versus markt: BTAI is forecast to remain unprofitable over the next 3 years.

Hoge groeiwinsten: BTAI is forecast to remain unprofitable over the next 3 years.

Omzet versus markt: BTAI's revenue (57.7% per year) is forecast to grow faster than the US market (8.9% per year).

Hoge groei-inkomsten: BTAI's revenue (57.7% per year) is forecast to grow faster than 20% per year.


Groeiprognoses winst per aandeel


Toekomstig rendement op eigen vermogen

Toekomstige ROE: Insufficient data to determine if BTAI's Return on Equity is forecast to be high in 3 years time


Ontdek groeibedrijven